{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:55:12Z","timestamp":1786996512047,"version":"build-2736575974"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003142","name":"NutsOhra Fund","doi-asserted-by":"publisher","award":["0901-071"],"award-info":[{"award-number":["0901-071"]}],"id":[{"id":"10.13039\/501100003142","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.schres.2024.09.007","type":"journal-article","created":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T23:37:18Z","timestamp":1726443438000},"page":"105-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Switching a combination of first- and second-generation antipsychotic polypharmacy to antipsychotic monotherapy in long-term inpatients with schizophrenia and related disorders. The SwAP trial II: Results on side effects"],"prefix":"10.1016","volume":"274","author":[{"given":"Mushde","family":"Shakir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter N.","family":"van Harten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan W.","family":"Hoogendoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E.","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederik E.","family":"Tenback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.schres.2024.09.007_bb0005","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1192\/bjp.163.2.150","article-title":"The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the UK","volume":"163","author":"Adams","year":"1993","journal-title":"Br. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2024.09.007_bb0010","doi-asserted-by":"crossref","first-page":"531","DOI":"10.4097\/kja.23278","article-title":"Intention-to-treat versus as-treated versus per-protocol approaches to analysis","volume":"76","author":"Ahn","year":"2023","journal-title":"Korean J. Anesthesiol."},{"issue":"S38","key":"10.1016\/j.schres.2024.09.007_bb0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1192\/S0007125000298097","article-title":"Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics","volume":"174","author":"Barnes","year":"1999","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.09.007_bb0020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/JPRLS.S99197","article-title":"Drug-induced parkinsonism: diagnosis and management","volume":"6","author":"Blanchet","year":"2016","journal-title":"Journal of Parkinsonism and Restless Legs Syndrome"},{"issue":"1","key":"10.1016\/j.schres.2024.09.007_bb0025","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.4088\/JCP.14m09321","article-title":"Switching from 2 to 1 antipsychotics in schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"77","author":"Borlido","year":"2016","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2024.09.007_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-016-1121-1","article-title":"Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: A cross-sectional study","volume":"16","author":"Bressington","year":"2016","journal-title":"BMC Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2024.09.007_bb0035","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s11096-006-9063-1","article-title":"Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study","volume":"29","author":"Broekema","year":"2007","journal-title":"Pharm. World Sci."},{"issue":"2","key":"10.1016\/j.schres.2024.09.007_bb0040","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-0447.2005.00589.x","article-title":"Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy","volume":"113","author":"Carnahan","year":"2006","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.schres.2024.09.007_bb0045","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0014-2999(90)90665-S","article-title":"Clozapine fails to prevent the development of haloperidol-induced behavioral hypersensitivity in a cotreatment paradigm","volume":"184","author":"Carvey","year":"1990","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.schres.2024.09.007_bb0050","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s11126-017-9494-y","article-title":"Reliability and validity of the short version of Udvalg for Kliniske Undersogelser in antipsychotic treatment","volume":"88","author":"Chen","year":"2017","journal-title":"Psychiatry Q."},{"issue":"4","key":"10.1016\/j.schres.2024.09.007_bb0055","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000477313","article-title":"Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy","volume":"86","author":"Chouinard","year":"2017","journal-title":"Psychother. Psychosom."},{"issue":"4","key":"10.1016\/j.schres.2024.09.007_bb0060","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000477313","article-title":"Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy","volume":"86","author":"Chouinard","year":"2017","journal-title":"Psychother. Psychosom."},{"issue":"6","key":"10.1016\/j.schres.2024.09.007_bb0065","first-page":"368","article-title":"Psychopharmacological treatment for schizophrenia: less is more","volume":"27","author":"Chuanyue","year":"2015","journal-title":"Shanghai Arch. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2024.09.007_bb0070","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1185\/03007995.2014.898139","article-title":"The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study","volume":"30","author":"Chue","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"issue":"8","key":"10.1016\/j.schres.2024.09.007_bb0075","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1185\/03007995.2014.908280","article-title":"A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults","volume":"30","author":"Citrome","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"issue":"1\u20133","key":"10.1016\/j.schres.2024.09.007_bb0080","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.schres.2015.05.038","article-title":"The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial","volume":"166","author":"Constantine","year":"2015","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2024.09.007_bb0085","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.schres.2015.05.038","article-title":"The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: A randomized controlled trial","volume":"166","author":"Constantine","year":"2015","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2024.09.007_bb0090","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.schres.2006.08.017","article-title":"Does antipsychotic polypharmacy increase the risk for metabolic syndrome?","volume":"89","author":"Correll","year":"2007","journal-title":"Schizophr. Res."},{"issue":"44","key":"10.1016\/j.schres.2024.09.007_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta24440","article-title":"Switching antipsychotic medication to reduce sexual dysfunction in people with psychosis: the REMEDY RCT","volume":"24","author":"Crawford","year":"2020","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.schres.2024.09.007_bb0100","series-title":"Sexual Dysfunctions in Mentally Ill Patients","first-page":"83","article-title":"Psychosis, antipsychotic medication, and sexual dysfunctions","author":"De Hert","year":"2018"},{"issue":"1","key":"10.1016\/j.schres.2024.09.007_bb0105","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/neurolint14010024","article-title":"Antipsychotic polypharmacy-related cardiovascular morbidity and mortality: A comprehensive review","volume":"14","author":"Edinoff","year":"2022","journal-title":"Neurol. Int."},{"issue":"7","key":"10.1016\/j.schres.2024.09.007_bb0110","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/appi.ajp.2011.10060908","article-title":"Effectiveness of switching from antipsychotic polypharmacy to monotherapy","volume":"168","author":"Essock","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.09.007_bb0115","series-title":"30th Psychiatric Congress","first-page":"16","article-title":"Tardive dyskinesia: patient and caregiver perspectives on signs, symptoms, and impact","author":"Farber","year":"2017"},{"issue":"9","key":"10.1016\/j.schres.2024.09.007_bb0120","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1176\/appi.ps.201800052","article-title":"Trends in and predictors of long-term antipsychotic polypharmacy use among Ohio Medicaid patients with schizophrenia, 2008\u20132014","volume":"69","author":"Fontanella","year":"2018","journal-title":"Psychiatr. Serv."},{"issue":"4","key":"10.1016\/j.schres.2024.09.007_bb0125","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0447.1993.tb03366.x","article-title":"The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity","volume":"87","author":"Gerlach","year":"1993","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2024.09.007_bb0130","series-title":"Meetinstrumenten bij motorische bijwerkingen. Tijdschrift voor Psychiatrie","first-page":"711","author":"van Harten","year":"2004"},{"key":"10.1016\/j.schres.2024.09.007_bb0135","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.4088\/JCP.v67n1212","article-title":"Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Cura\u00e7ao extrapyramidal syndromes study V","volume":"67","author":"van Harten","year":"2006","journal-title":"J. Clin. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2024.09.007_bb0140","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.schres.2006.05.004","article-title":"Antipsychotic medication and cognitive function in schizophrenia","volume":"86","author":"Hori","year":"2006","journal-title":"Schizophr. Res."},{"issue":"12","key":"10.1016\/j.schres.2024.09.007_bb0145","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.jpsychires.2013.08.024","article-title":"Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients","volume":"47","author":"Hori","year":"2013","journal-title":"Psychiatric Research"},{"issue":"4","key":"10.1016\/j.schres.2024.09.007_bb0150","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1176\/ajp.156.4.631","article-title":"Sexual disturbances during clozapine and haloperidol treatment for schizophrenia","volume":"156","author":"Hummer","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.09.007_bb0155","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.2147\/NDT.S310605","article-title":"Assessment of the impact of tardive dyskinesia in clinical practice: consensus panel recommendations","volume":"17","author":"Jackson","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"1","key":"10.1016\/j.schres.2024.09.007_bb0160","doi-asserted-by":"crossref","first-page":"159","DOI":"10.9758\/cpn.2020.18.1.159","article-title":"Effectiveness in switching from antipsychotic polypharmacy to monotherapy in patients with schizophrenia: a case series","volume":"18","author":"Kamei","year":"2020","journal-title":"Clinical Psychopharmacology and Neuroscience"},{"issue":"1","key":"10.1016\/j.schres.2024.09.007_bb0165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00213-002-1052-z","article-title":"Subjective well-being and quality of life under atypical antipsychotic treatment","volume":"162","author":"Karow","year":"2002","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2024.09.007_bb0170","first-page":"75","article-title":"Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia","volume":"68","author":"Karow","year":"2007"},{"issue":"9","key":"10.1016\/j.schres.2024.09.007_bb0175","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2024.09.007_bb0180","doi-asserted-by":"crossref","first-page":"968","DOI":"10.30773\/pi.2021.0190","article-title":"Associations of clozapine use with psychosocial functioning and quality of life in patients with schizophrenia: a community-based cross-sectional study","volume":"18","author":"Kim","year":"2021","journal-title":"Psychiatry Investig."},{"issue":"1","key":"10.1016\/j.schres.2024.09.007_bb0185","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/JCP.0b013e3181c914b3","article-title":"Systematic evaluation of rating scales for drug-induced parkinsonism and recommendations for future research","volume":"30","author":"Knol","year":"2010","journal-title":"Clinical Psychopharmacology"},{"issue":"7","key":"10.1016\/j.schres.2024.09.007_bb0190","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1176\/ps.2007.58.7.983","article-title":"Adding or switching antipsychotic medications in treatment-refractory schizophrenia","volume":"58","author":"Kreyenbuhl","year":"2007","journal-title":"Psychiatr. Serv."},{"issue":"1","key":"10.1016\/j.schres.2024.09.007_bb0195","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/bmb\/ldv017","article-title":"Antipsychotic medication in schizophrenia: a review","volume":"114","author":"Lally","year":"2015","journal-title":"Br. Med. Bull."},{"issue":"2","key":"10.1016\/j.schres.2024.09.007_bb0200","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1192\/pb.bp.108.024257","article-title":"Antipsychotic polypharmacy: review of mechanisms, mortality and management","volume":"34","author":"Langan","year":"2010","journal-title":"Psychiatrist"},{"issue":"suppl_1","key":"10.1016\/j.schres.2024.09.007_bb0205","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","article-title":"Dose equivalents for antipsychotic drugs: the DDD method","volume":"42","author":"Leucht","year":"2016","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2024.09.007_bb0210","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"76","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr. Scand."},{"issue":"S1","key":"10.1016\/j.schres.2024.09.007_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852915000838","article-title":"The clinical challenges of akathisia","volume":"20","author":"Lohr","year":"2015","journal-title":"CNS Spectr."},{"key":"10.1016\/j.schres.2024.09.007_bb0220","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2019.05.030","article-title":"Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: a systematic review and meta-analysis","volume":"209","author":"Matsui","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.09.007_bb0225","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1007\/s11136-019-02269-8","article-title":"Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia","volume":"28","author":"McEvoy","year":"2019","journal-title":"Journal of Quality of Life Research"},{"issue":"4","key":"10.1016\/j.schres.2024.09.007_bb0230","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1192\/bjp.bp.108.050088","article-title":"Extrapyramidal side-effects of antipsychotics in a randomised trial","volume":"193","author":"Miller","year":"2008","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.09.007_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-244X-11-118","article-title":"Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study","volume":"11","author":"Misawa","year":"2011","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2024.09.007_bb0240","doi-asserted-by":"crossref","first-page":"7055","DOI":"10.4088\/JCP.18m12246","article-title":"Prevalence of and risk factors for extrapyramidal side effects of antipsychotics: results from the national FACE-SZ cohort","volume":"80","author":"Misdrahi","year":"2019","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2024.09.007_bb0245","article-title":"Severity of tardive dyskinesia and negative symptoms are associated with poor quality of life in schizophrenia patients","volume":"20","author":"Othman","year":"2013","journal-title":"Intern. Med. J."},{"issue":"6","key":"10.1016\/j.schres.2024.09.007_bb0250","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/01.pra.0000341890.05383.45","article-title":"Polypharmacy with second-generation antipsychotics: a review of evidence","volume":"14","author":"Pandurangi","year":"2008","journal-title":"J. Psychiatr. Pract."},{"issue":"4","key":"10.1016\/j.schres.2024.09.007_bb0255","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/schbul\/sbab028","article-title":"Exploring the relationship between movement disorders and physical activity in patients with schizophrenia: an actigraphy study","volume":"47","author":"Pieters","year":"2021","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2024.09.007_bb0260","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1755-5949.2010.00162.x","article-title":"All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors","volume":"17","author":"Seeman","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.schres.2024.09.007_bb0265","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.schres.2022.03.008","volume":"243","author":"Shakir","year":"2022","journal-title":"Schizophr. Res."},{"issue":"2000","key":"10.1016\/j.schres.2024.09.007_bb0270","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s002130000532","article-title":"Increased dopamine D 2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study","volume":"152","author":"Silvestri","year":"2000","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.09.007_bb0275","article-title":"Clinical, biochemical and genetic variables associated with metabolic syndrome in patients with schizophrenia spectrum disorders using second-generation antipsychotics: a systematic review","volume":"12","author":"Sneller","year":"2021","journal-title":"Front. Psychol."},{"key":"10.1016\/j.schres.2024.09.007_bb0280","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first-and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"Solmi","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"issue":"4","key":"10.1016\/j.schres.2024.09.007_bb0285","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/13651500050517894","article-title":"Relationship of akathisia to aggressive and self-injurious behaviour: a prevalence study in a UK tertiary referral Centre","volume":"4","author":"Stubbs","year":"2000","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"102","key":"10.1016\/j.schres.2024.09.007_bb0290","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0920-9964(08)70727-8","article-title":"Incidence and subsequent persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia in the new antipsychotics era","volume":"1","author":"Tenback","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.09.007_bb0295","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/B978-0-12-381328-2.00009-2","article-title":"Epidemiology and risk factors for (tardive) dyskinesia","volume":"98","author":"Tenback","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"issue":"7","key":"10.1016\/j.schres.2024.09.007_bb0300","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/nep.13709","article-title":"Intention to treat and per protocol analysis in clinical trials","volume":"25","author":"Tripepi","year":"2020","journal-title":"Nephrology"},{"issue":"2","key":"10.1016\/j.schres.2024.09.007_bb0305","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/08039488.2020.1811374","article-title":"Effectiveness of clozapine on quality of life and functioning in patients with treatment-resistant schizophrenia","volume":"75","author":"Verma","year":"2021","journal-title":"Nord. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2024.09.007_bb0310","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1517\/14740338.2014.935761","article-title":"Safety of antipsychotic drugs: focus on therapeutic and adverse effects","volume":"13","author":"Werner","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"issue":"4","key":"10.1016\/j.schres.2024.09.007_bb0315","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/schbul\/sbac037","article-title":"Movement disorders and mortality in severely mentally ill patients: the curacao extrapyramidal syndromes study XIV","volume":"48","author":"Willems","year":"2022","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2024.09.007_bb0320","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.609240","article-title":"A focused review of the metabolic side-effects of clozapine","volume":"12","author":"Yuen","year":"2021","journal-title":"Front. Endocrinol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424004079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424004079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T16:39:09Z","timestamp":1757349549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996424004079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":64,"alternative-id":["S0920996424004079"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2024.09.007","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching a combination of first- and second-generation antipsychotic polypharmacy to antipsychotic monotherapy in long-term inpatients with schizophrenia and related disorders. The SwAP trial II: Results on side effects","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2024.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}